Drugs in R & D

, Volume 4, Issue 1, pp 19–28

Efficacy of Rebamipide as Adjunctive Therapy in the Treatment of Recurrent Oral Aphthous Ulcers in Patients with Behçet’s Disease

A Randomised, Double-Blind, Placebo-Controlled Study
  • Takahide Matsuda
  • Shigeaki Ohno
  • Shunsei Hirohata
  • Yoshitaka Miyanaga
  • Hiroshi Ujihara
  • Goro Inaba
  • Satoshi Nakamura
  • Shun-ichi Tanaka
  • Mitsuko Kogure
  • Yutaka Mizushima
Original Research Article

Abstract

Background: Behçet’s disease (BD) is a recurrent inflammatory disease involving chronic recurrent oral aphthous ulcers (aphthae), uveitis, skin lesions and genital ulcers. We prospectively investigated the efficacy of rebamipide, a gastroprotective drug, against oral aphthous ulcers in BD patients.

Methods: In a multicentre, double-blind, placebo-controlled study, 35 patients with BD, having as the main symptom oral aphthosis, were randomised to receive rebamipide 300 mg/day or placebo for 12 to 24 weeks between August 1994 and December 1996. Oral aphthosis must have occurred within 4 weeks prior to enrolment and must have been visible for at least 7 days during that time. Oral aphthae count and pain scores were recorded daily in a diary by the patients themselves. Monthly aphthae count and pain scores were defined as the sum of aphthae count and pain scores for a month, respectively. Investigators rated the global improvement in aphthae count and pain using a 6-point scale. The rate of change in monthly aphthae count and pain scores in the first 3 and last 3 months of treatment were assessed in patients with more severe symptoms whose aphthae count and pain score were >28 at baseline (trial entry).

Results: The rate of moderate or marked improvement in aphthae count and pain was 36% (5 of 14 subjects) in the placebo group and 65% (11 of 17 subjects) in the rebamipide group. During months 2 to 6 of treatment, aphthae count tended to increase and reached a peak at month 4 in the placebo group but decreased in the rebamipide group. Pain score decreased to the same extent in both groups for the first 3 months of treatment; however, in the fourth to sixth months of treatment, the pain score tended to increase in the placebo group but decreased in the rebamipide group. In patients with a monthly aphthae pain score >28 at baseline, pain and count scores decreased throughout the 6 months of rebamipide treatment but increased during the last 3 months of treatment in the placebo group (p < 0.01 for the between-group comparisons).

Conclusions: Rebamipide is well tolerated and improves the aphthae count and pain score in BD patients. It may therefore be useful in the treatment and prevention of frequently recurrent oral aphthous ulcers (not restricted to BD). Administration of rebamipide is not cumbersome, and it does not cause any discomfort, which corticosteroid ointments for example may do; furthermore, there are no specific adverse drug reactions. Rebamipide is therefore recommended as a long-term treatment for recurrent oral aphthous ulcers.

References

  1. 1.
    Matsuda T, Mizushima Y. Fifteen years of progress in the study of Behçet’s disease: etiology, pathogenesis, therapy. Saishin Igaku 1988; 43: 249–58Google Scholar
  2. 2.
    Niwa Y, Miyake S. Auto-oxidative damage in Behçet’s disease: endothelial damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 1982; 4: 247–55Google Scholar
  3. 3.
    Matsuda T, Yamada H, Hoshi K, et al. The beneficial effect of rebamipide on recurrent oral aphthous ulcers in Behçet’s disease. J Clin Exp Med 1994; 170: 773–4Google Scholar
  4. 4.
    Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet’s disease. Semin Arthritis Rheum 1998; 27: 197–217PubMedCrossRefGoogle Scholar
  5. 5.
    Matsuda T, Tanaka C, Imamura Y. Behçet’s disease. Medical Postgraduates 2000; 38: 112–21Google Scholar
  6. 6.
    Uchida M, Tabusa F, Komatsu M, et al. Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl] propionic acid and related compounds. Chem Pharm Bull (Tokyo) 1985; 33: 3775–86CrossRefGoogle Scholar
  7. 7.
    Shiraki M, Yamasaki K, Ishiyama H, et al. Healing promoting effect of proamipide, a novel drug that increases gastric defense mechanisms, on acetic-induced gastric ulcers in the rat. Folia Pharmacol Japon 1988; 92: 389–95CrossRefGoogle Scholar
  8. 8.
    Yamasaki K, Kanbe T, Chijiwa T, et al. Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur J Pharmacol 1987; 142: 23–9PubMedCrossRefGoogle Scholar
  9. 9.
    Nakamura H, Arakawa T, Kobayashi K, et al. Mucosal protective action of proamipide (OPC-12759) against gastric mucosal cell damage. J Adult Dis 1989; 19: 1109–14Google Scholar
  10. 10.
    Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 1993; 38: 1441–9PubMedCrossRefGoogle Scholar
  11. 11.
    Suzuki M, Miura S, Mori M, et al. Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut 1994; 35: 1375–8PubMedCrossRefGoogle Scholar
  12. 12.
    Yoshikawa T, Naito Y, Nakamura S, et al. Effect of rebamipide on lipid peroxidation and gastric mucosal injury induced by indomethacin in rats. Arzneimittel Forschung 1993; 43 (II) 12: 1327–30PubMedGoogle Scholar
  13. 13.
    Yoshikawa T, Naito Y, Tanigawa T, et al. Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittel Forschung 1993; 43 (I) 3: 363–6PubMedGoogle Scholar
  14. 14.
    Inaba G. Diagnostic criteria of Behçet’s disease. Clin Immunol 1983; 15: 370–81Google Scholar
  15. 15.
    Arakawa T, Kobayashi K, Yoshikawa T, et al. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 1998; 43 (9): 5S–13SPubMedGoogle Scholar
  16. 16.
    Sun WH, Tsuji S, Tsujii M, et al. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J Pharmacol Exp Ther 2000; 295 (2): 447–52PubMedGoogle Scholar
  17. 17.
    Tarnawski A, Arakawa T, Kobayashi K. Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci 1998; 43 (9): 90S–8SPubMedGoogle Scholar
  18. 18.
    Wu-Wang CY, Patel M, Feng J, et al. Decreased levels of salivary prostaglandin E2 and epidermal growth factor in recurrent aphthous stomatitis. Arch Oral Biol 1995; 40 (12): 1093–8PubMedCrossRefGoogle Scholar
  19. 19.
    Ishihara K, Komoru Y, Nishiyama N, et al. Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism. Arzneimittel Forschung 1992; 42: 1462–6PubMedGoogle Scholar
  20. 20.
    Suetsugu H, Ishihara S, Moriyama N, et al. Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J Lab Clin Med 2000; 136 (1): 50–7PubMedCrossRefGoogle Scholar
  21. 21.
    Ogino K, Hobara T, Ishiyama H, et al. Antiulcer mechanism of action of rebamipide, a novel antiulcer compound, on diethyldithiocarbamate-induced antral gastric ulcers in rats. Eur J Pharmacol 1992; 212: 9–13PubMedCrossRefGoogle Scholar
  22. 22.
    Naito Y, Yoshikawa T, Tanigawa T, et al. Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med 1995; 18: 117–23PubMedCrossRefGoogle Scholar
  23. 23.
    Watanabe S, Wang X-E, Hirose M, et al. Effects of rebamipide on bile acid-induced inhibition of gastric epithelial repair in a rabbit cell culture model. Aliment Pharmacol Ther 1996; 10: 927–32PubMedCrossRefGoogle Scholar
  24. 24.
    Naito Y, Yoshikawa T, Iinuma S, et al. Local gastric and serum concentrations of rebamipide following oral administration to patients with chronic gastritis. Arzneim-Forsch 1996; 46: 698–700Google Scholar
  25. 25.
    Akamatsu T, Nakamura N, Furuya N, et al. Local gastric and serum concentrations of rebampidie following oral ingestion in healthy volunteers. Dig Dis Sci 2002: 47: 1399–1404 1988; 92: 389–95PubMedCrossRefGoogle Scholar
  26. 26.
    Ishiyama H, Kawai K, Azuma A, et al. Therapeutic effect of rebamipide in a modified acetic acid-induced buccal mucosal ulcer model. Inflammopharmacology. In pressGoogle Scholar
  27. 27.
    Hong KW, Kim KE, Rhim BY, et al. Effect of rebamipide on liver damage and increased tumor necrosis factor in a rat model of endotoxin shock. Dig Dis Sci 1998; 43: 154S–9SPubMedGoogle Scholar
  28. 28.
    Murakami N, Hara H, Hashimoto M, et al. Effect of oral administration of rebamipide on laryngeal granuloma. Larynx Jpn 2002; 14: 53Google Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  • Takahide Matsuda
    • 1
  • Shigeaki Ohno
    • 2
  • Shunsei Hirohata
    • 3
  • Yoshitaka Miyanaga
    • 4
  • Hiroshi Ujihara
    • 4
  • Goro Inaba
    • 4
  • Satoshi Nakamura
    • 2
  • Shun-ichi Tanaka
    • 5
  • Mitsuko Kogure
    • 6
  • Yutaka Mizushima
    • 1
  1. 1.Institute of Medical ScienceSt Marianna University School of MedicineKawasaki, KanagawaJapan
  2. 2.Department of OphthalmologyYokohama City University School of MedicineYokohamaJapan
  3. 3.Department of Internal MedicineTeikyo University School of MedicineTokyoJapan
  4. 4.Department of OphthalmologyTokyo Women’s Medical University Daini HospitalTokyoJapan
  5. 5.Third Department of Internal MedicineYokohama City University School of MedicineYokohamaJapan
  6. 6.Department of OphthalmologyTokyo Women’s Medical University School of MedicineTokyoJapan

Personalised recommendations